EP4441043A1 — Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates
Assigned to Assia Chemical Industries Ltd · Expires 2024-10-09 · 2y expired
What this patent protects
The present disclosure encompasses solid state forms of Deucravacitinib : L- tartaric acid or Deucravacitinib - L-tartrate, as well as processes for preparation of Deucravacitinib and intermediates thereof.
USPTO Abstract
The present disclosure encompasses solid state forms of Deucravacitinib : L- tartaric acid or Deucravacitinib - L-tartrate, as well as processes for preparation of Deucravacitinib and intermediates thereof.
Drugs covered by this patent
- Sotyktu (DEUCRAVACITINIB) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.